Ozempic May Reduce Oxygen Supply to Developing Fetuses, Animal Study Finds

Researchers at Adelaide University found that semaglutide, the active ingredient in Ozempic, reduced uterine blood flow and oxygen levels in fetuses during an animal study involving seven pregnant sheep. The changes appeared within two hours of the animals receiving a dose. The findings have not been validated in humans, and the researchers say pregnant women are already advised not to use GLP-1 drugs.